Therapy Area Review and Prioritization of Opportunities
Our client, a clinical-stage biopharmaceutical company, was heavily dependent on and known for one therapeutic area (TA). They had a number of assets in pre-clinical development with potential in a several different diseases in a new therapy area and wished to broaden their development portfolio accordingly but needed help in evaluating and prioritizing the best disease opportunities to pursue in terms of scientific rationale, unmet medical need and commercial potential.
Psscion worked collaboratively with the client, including facilitating two workshop sessions, to comprehensively review 8 disease areas and build Target Product Profiles (TPP’s) for each including forecasts of peak sales potential and key clinical, regulatory and reimbursement/access hurdles to be addressed with an overall probability of success agreed. Key elements included:
Three disease areas/ TPP’s were prioritized to move into development. These, supported by the above analysis, were presented to the Client’s Board of Directors and endorsed/ funded to be taken forward into development. In one disease area where we have particular expertise, we were also asked to provide recommendations for rapid (max 28 day) proof of principle studies to quickly confirm human efficacy together with suggested KoL’s/ Centers to conduct such studies. The Client issued a press release announcing their entry into the new TA/DA’s and subsequently acquired rights to an additional library of compounds complementary to their own internal assets.